Citable filing context
BAX's research view summarizes recent SEC filing context, starting with management_change from Aug 19, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 19, 2026 | management_change | Baxter International appointed John Rogers as Chief Financial Officer, effective October 1, 2026. |
| Aug 18, 2026 | debt_offering | Baxter increased its cash tender offer cap for senior notes to $600 million and amended its credit agreement. |
| Aug 4, 2026 | debt_offering | Baxter International commenced cash tender offers to purchase up to $500 million of its outstanding senior notes. |
| Jul 30, 2026 | Guidance: adjusted_diluted_eps | 1.95 to 2.15 |
| Jul 30, 2026 | Guidance: organic_sales_growth | 2.00 to 3.00 |
| Jul 30, 2026 | Guidance: reported_sales_growth | 3.00 to 4.00 |
| Jul 30, 2026 | mda_quarterly | Baxter International’s financial performance for the first half of 2026 reflects a strategic pivot following the January 2025 divestiture of its Kidney Care business. The company has reorganized into two primary reportable segments: Medical Products & Therapies and Healthcare Systems & Technologies. Net sales for the second quarter of 2026 reached $2.96 billion, a 5% increase year-over-year, though profitability remains pressured by manufacturing and supply chain costs, including impacts from Hurricane Helene and ongoing inflationary trends. A critical operational headwind is the voluntary Class I recall of the Novum IQ Large Volume Pump (LVP). Baxter has suspended distribution and installation of the device in the U.S. and Canada, leading to a cessation of meaningful sales for this product line. While the company recorded $75 million in tariff refunds under the IEEPA in the second quarter, it continues to face risks from global trade policies and potential future tariffs. Financially, the company is focused on cost structure transformation and debt management. Following the Kidney Care sale, Baxter utilized proceeds to pay down significant legacy debt. However, the company maintains a cautious outlook, citing supply constraints, geopolitical volatility, and legal contingencies, including ongoing DOJ investigations and securities litigation related to the Novum LVP. |
| Apr 30, 2026 | mda_quarterly | Baxter reported a net loss of $15 million for the first quarter of 2026, compared to a $126 million profit in the prior year. Total net sales increased 3% to $2.7 billion, though organic sales growth declined 1%. The company completed the divestiture of its Kidney Care business to Carlyle Group, receiving $3.2 billion in after-tax proceeds to reduce legacy indebtedness. Financial performance was heavily impacted by Class I recalls and shipment holds for the Novum IQ Large Volume Pump in the U.S. and Canada, which are expected to eliminate meaningful sales of the product until holds are lifted. Within the Medical Products & Therapies segment, Advanced Surgery grew 13% driven by hemostats and sealants. The Pharmaceuticals segment saw a 30% increase in Drug Compounding, offset by a 10% decline in Injectables & Anesthesia due to supply constraints and lower global anesthesia demand. Key risks include Section 122 tariffs, inflationary pressures on labor and shipping, and geopolitical volatility. Consequently, S&P and Moody's revised Baxter's credit outlook to Negative. To mitigate dis-synergies from the Kidney Care sale, the company incurred $68 million in business optimization charges during the quarter. |
Source: SEC EDGAR filing text and events; period Aug 19, 2026; filed Aug 19, 2026.
BAX company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.